STRO Sutro Biopharma, Inc. - Common Stock
$22.94
가격 · 8월 19, 2026
기준 재무 정보 8월 12, 2026
52주 범위
$1–$44
51% of range
애널리스트 평점
BUY
19 analysts
목표 주가
$48
+108% upside
P/E (TTM)
-1.0
ROE
232.2%
순이익률
-186.5%
Sutro Biopharma, Inc. - Common Stock 정보 위키백과 회사 개요
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
더 보기
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.
As of 2024 Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically validated targets for which the current standard of care is suboptimal.
Technology
Sutro's Xpress CF Platform is based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology. XpressCF technology enables the parallel expression of hundreds of protein variants in less than 24 hours, providing a platform for the discovery and development of a wide variety of protein classes including cytokines, vaccine carrier-proteins, antibodies, and novel antibody-based proteins. The XpressCF+ platform allows for precise incorporation of non-natural amino acids into a protein sequence, and Sutro is using this technology to develop homogeneous site-specific antibody-drug conjugates (ADCs). Once identified, production of protein drug candidates can be scaled in Sutro's cGMP manufacturing facility located in San Carlos, CA.
Sutro's technology has also contributed to the formation of SutroVax, a vaccine spin off founded in 2015 that has raised over US$170 million in capital.
Collaborations
In July 2018, Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration. In 2017, Sutro and Celgene announced they had refocused their 2014 immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen (BCMA).
Awards
The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce Biotech's Fierce 15 in 2014. In 2015 was awarded the DiNA Outstanding Partner Award by the California Life Sciences Association.
== References ==
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
STRO 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$22.94
시가총액
$197M
P/E (TTM)
-1.0
EPS (TTM)
$-22.49
매출 (TTM)
$102M
배당 수익률
—
ROE
232.2%
부채/자본
—
52주 범위
$1 – $44
STRO 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$102M
2016-12-31
→
2025-12-31
EPS
$-22.49
2020-12-31
→
2025-12-31
잉여현금흐름
—
2018-12-31
→
2018-12-31
마진
-186.5%
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
STRO
동종업계 중앙값
P/E (TTM)
-1.0
6.1
P/S (TTM)
1.9
7.7
P/B
-1.5
2.2
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
STRO
동종업계 중앙값
Operating Margin (영업이익률)
-154.5%
—
Net Profit Margin (순이익률)
-186.5%
-60.9%
ROA
-68.1%
-50.0%
ROE
232.2%
-44.8%
ROIC
119.5%
—
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
STRO
동종업계 중앙값
Current Ratio (유동비율)
2.0
5.9
Quick Ratio (당좌 비율)
1.9
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
STRO
동종업계 중앙값
Revenue YoY (매출 YoY)
65.2%
—
Revenue CAGR 3Y (매출 CAGR 3년)
14.8%
—
Revenue CAGR 5Y (매출 CAGR 5년)
19.1%
—
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
STRO
동종업계 중앙값
STRO 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
매수
19 명의 애널리스트
- 적극 매수 5 26.3%
- 매수 12 63.2%
- 보유 1 5.3%
- 매도 1 5.3%
- 적극 매도 0 0.0%
12개월 목표 주가
13 명의 애널리스트 · 2026-08-13
중앙값
$50.00
지금
$22.94
저가
$10.00
고가
$61.00
중앙값 목표
$50.00
+118.0%
평균 목표
$47.77
+108.2%
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
-0.34%
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 3월 31일 | $-2.94 | $-3.85 | 0.91% |
| 2025년 12월 31일 | $-5.29 | $-4.43 | -0.86% |
| 2025년 9월 30일 | $-6.70 | $-4.23 | -2.5% |
| 2025년 6월 30일 | $-1.40 | $-4.10 | 2.7% |
| 2025년 3월 31일 | $-9.10 | $-7.22 | -1.9% |
| 2024년 12월 31일 | $-8.90 | $-8.48 | -0.42% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| STRO | $99M | -0.5 | 65.2% | -186.5% | 232.2% | — |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | — |
| DMAC | $428M | — | — | — | -78.7% | — |
| GALT | $271M | -8.7 | — | — | 25.0% | — |
| ZNTL | $93M | -0.7 | — | — | -49.5% | — |
| IPSC | $87M | -7.1 | 1556.8% | -8.8% | -5.2% | — |
| SABS | — | — | — | — | — | — |
| ABEO | $290M | 5.2 | 147.5% | 1223.1% | 44.1% | — |
| IMRX | — | -5.2 | — | — | -45.3% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 15
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | $52M | |
| R&D Expense | $166M | $252M | $180M | $137M | $104M | $77M | $66M | $54M | $55M | |
| SG&A Expense | $41M | $48M | $63M | $60M | $56M | $37M | $33M | $21M | $16M | |
| Operating Expenses | $261M | $300M | $243M | $197M | $160M | $114M | $98M | $76M | $71M | |
| Operating Income | $-158M | $-238M | $-89M | $-129M | $-99M | $-71M | $-55M | $-37M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | $2M | $612.0K | |
| Other Non-op | · | · | · | · | · | · | · | $2M | $-77.0K | |
| Pretax Income | $-191M | $-225M | $-89M | $-117M | $-106M | $-32M | · | · | · | |
| Income Tax | $-93.0K | $2M | $18M | $2M | $0 | $103.0K | $0 | $0 | $0 | |
| Net Income | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | $-20M | |
| EPS (Basic) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| EPS (Diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| Shares (Basic) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| Shares (Diluted) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| EBITDA | $-151M | $-231M | $-82M | $-123M | $-94M | $-67M | · | $-33M | · |
대차대조표 24
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $190M | $69M | $47M | $30M | $206M | $5M | $125M | $22M | |
| Short-term Investments | $83M | $127M | $264M | $255M | $130M | $120M | $113M | $79M | · | |
| Receivables | $4M | $9M | $36M | $7M | $12M | $6M | $6M | $2M | $2M | |
| Prepaid Expense | $6M | $18M | $10M | $12M | $8M | $4M | $4M | $3M | $2M | |
| Current Assets | $151M | $343M | $422M | $353M | $219M | $378M | $129M | $210M | $26M | |
| PP&E (Net) | $11M | $18M | $22M | $25M | $23M | $13M | $10M | $11M | $14M | |
| PP&E (Gross) | $38M | $67M | $64M | $63M | $56M | $50M | $43M | $40M | $39M | |
| Accum. Depreciation | $27M | $49M | $42M | $38M | $33M | $37M | $34M | $29M | $25M | |
| Other Non-current Assets | $495.0K | $7M | $4M | $2M | $2M | $2M | $3M | $2M | $1M | |
| Total Assets | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Accounts Payable | $8M | $10M | $9M | $5M | $6M | $6M | $6M | $3M | $3M | |
| Accrued Liabilities | $15M | $13M | $15M | $13M | $11M | $9M | $6M | $6M | $4M | |
| Current Liabilities | $75M | $132M | $94M | $67M | $42M | $30M | $33M | $36M | $32M | |
| Capital Leases | $8M | $16M | $23M | $30M | $31M | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $2M | $119.0K | $146.0K | $481.0K | $134.0K | $102.0K | $14.0K | |
| Total Liabilities | $306M | $343M | $321M | $190M | $89M | $62M | $59M | $92M | $47M | |
| Long-term Debt | · | · | $4M | $16M | $25M | $25M | · | $15M | · | |
| Total Debt | · | · | $4M | $16M | $25M | $25M | · | $10M | · | |
| Common Stock | $9.0K | $8.0K | $61.0K | $58.0K | $46.0K | $46.0K | $23.0K | $23.0K | · | |
| Retained Earnings | $-978M | $-787M | $-559M | $-453M | $-333M | $-228M | $-196M | $-150M | $-115M | |
| AOCI | $19.0K | $39.0K | $21.0K | $-618.0K | $-314.0K | $129.0K | $165.0K | $-47.0K | · | |
| Stockholders' Equity | $-132M | $45M | $150M | $217M | $253M | $332M | $98M | $132M | $-109M | |
| Liabilities + Equity | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Shares Outstanding | 8,584,309 | 8,306,398 | 61,009,829 | 57,499,541 | 46,327,131 | 45,752,116 | 23,098,969 | 22,848,184 | 465,330 |
현금 흐름 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $7M | $6M | $5M | $4M | $5M | $5M | $5M | |
| Stock-based Comp | $14M | $25M | $25M | $26M | $23M | $12M | $10M | $3M | $1M | |
| Restructuring | $13M | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-7M | $4M | $-37M | $91M | $-4M | $-52M | · | $41M | · | |
| Operating Cash Flow | $-177M | $-192M | $-112M | $4M | $-82M | $-68M | $-65M | $13M | $-37M | |
| CapEx | · | · | · | · | · | · | · | $2M | $3M | |
| Investing Cash Flow | $45M | $219M | $-4M | $-35M | $-97M | $604.0K | $-51M | $-80M | $33M | |
| Debt Issued | · | · | · | · | · | · | · | $0 | $15M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | · | |
| Stock Issued | $0 | $25M | $0 | $0 | · | $251M | $-327.0K | · | · | |
| Stock Repurchased | · | · | · | · | $7.0K | · | · | · | · | |
| Net Stock Activity | $0 | $25M | $12M | $56M | $-7.0K | $251M | · | · | · | |
| Financing Cash Flow | $44.0K | $94M | $138M | $48M | $3M | $269M | $-4M | $171M | $15M | |
| Net Change in Cash | $-132M | $121M | $22M | $17M | $-176M | $202M | $-120M | $103M | $10M | |
| Taxes Paid | $75.0K | $18M | $379.0K | $0 | $103.0K | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | $11M | · |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | · | -96.9% | · | |
| Net Margin | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | · | -91.9% | · | |
| Pretax Margin | -186.5% | -362.8% | -57.6% | -172.2% | · | · | · | · | · | |
| EBITDA Margin | -147.4% | -372.7% | -53.6% | -181.9% | -151.4% | -156.3% | · | -85.1% | · | |
| ROA | -68.1% | -53.0% | -24.3% | -31.9% | -28.7% | -11.7% | · | -26.8% | · | |
| ROE | 232.2% | -292.0% | -81.5% | -53.4% | -39.4% | -11.2% | · | 713.8% | · | |
| ROIC | 119.5% | -540.2% | -70.0% | -56.5% | · | · | · | · | · |
유동성 및 지급능력 5
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 | 12.8 | · | 5.8 | · | |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 | 11.2 | · | 5.7 | · | |
| Debt / Equity | · | · | 0.0 | 0.1 | 0.1 | 0.1 | · | 0.1 | · | |
| LT Debt / Equity | · | · | 0.0 | 0.0 | 0.1 | 0.1 | · | 0.1 | · | |
| Interest Coverage | · | · | · | · | · | · | · | -22.9 | · |
효율성 2
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 | 0.4 | 0.2 | 0.2 | 0.2 | · | 0.3 | · | |
| Receivables Turnover | 16.3 | 2.8 | 7.1 | 6.9 | 6.9 | 7.2 | · | 18.7 | · |
성장률 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | -59.6% | 126.8% | 9.5% | 44.8% | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 0.09% | 53.2% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.1% | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 14
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | · | |
| Net Income TTM | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | · | |
| Market Cap | $99M | $152M | $262M | $465M | $689M | $993M | · | $206M | · | |
| Enterprise Value | · | · | $-68M | $179M | $554M | $691M | · | $12M | · | |
| P/E | -0.5 | -0.1 | -2.4 | -3.4 | -6.5 | -21.9 | · | · | · | |
| P/S | 1.0 | 2.4 | 1.7 | 6.9 | 11.1 | 23.2 | · | 5.4 | · | |
| P/B | -0.7 | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | 1.6 | · | |
| P / Tangible Book | · | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | · | · | |
| P / Cash Flow | -0.6 | -0.8 | -2.3 | 130.9 | -8.4 | -14.6 | · | 16.2 | · | |
| P / FCF | · | · | · | · | · | · | · | 18.5 | · | |
| EV / EBITDA | · | · | 0.8 | -1.4 | -5.9 | -10.4 | · | -0.4 | · | |
| EV / FCF | · | · | · | · | · | · | · | 1.0 | · | |
| EV / Revenue | · | · | -0.4 | 2.6 | 8.9 | 16.2 | · | 0.3 | · | |
| Earnings Yield | -194.4% | -1597.8% | -41.5% | -29.1% | -15.4% | -4.6% | · | · | · |
손익계산서 13
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $12M | $10M | $64M | $17M | $15M | $9M | $26M | $13M | $114M | $17M | $10M | $13M | $9M | $25M | |
| R&D Expense | $32M | $37M | $37M | $40M | $38M | $52M | $71M | $62M | $62M | $57M | $54M | $46M | $42M | $39M | $43M | $32M | |
| SG&A Expense | $8M | $8M | $9M | $9M | $10M | $13M | $9M | $14M | $12M | $13M | $17M | $15M | $15M | $16M | $15M | $15M | |
| Operating Expenses | $40M | $44M | $50M | $58M | $67M | $86M | $80M | $76M | $74M | $70M | $71M | $61M | $57M | $55M | $58M | $46M | |
| Operating Income | $-30M | $-30M | $-38M | $-48M | $-3M | $-69M | $-65M | $-68M | $-49M | $-57M | $43M | $-44M | $-46M | $-42M | $-49M | $-21M | |
| Pretax Income | $-39M | $-38M | $-47M | $-57M | $-12M | $-76M | $-70M | $-49M | $-48M | $-58M | $47M | $-47M | $-38M | $-50M | $-35M | $-19M | |
| Income Tax | $1.0K | $-15.0K | $-82.0K | $0 | $-18.0K | $7.0K | $2M | $0 | $8.0K | · | $16M | $2M | $151.0K | $395.0K | $0 | $0 | |
| Net Income | $-39M | $-38M | $-47M | $-57M | $-11M | $-76M | $-72M | $-49M | $-48M | $-58M | $31M | $-49M | $-39M | $-50M | $-35M | $-19M | |
| EPS (Basic) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| EPS (Diluted) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| Shares (Basic) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| Shares (Diluted) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| EBITDA | $-30M | $-28M | · | $-48M | $-3M | $-67M | · | $-68M | $-49M | $-55M | · | $-44M | $-46M | $-41M | · | $-21M |
대차대조표 23
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $74M | $58M | $66M | $64M | $106M | $190M | $175M | $91M | $65M | $69M | $82M | $235M | $62M | $47M | $97M | |
| Short-term Investments | $110M | $129M | $83M | $102M | $141M | $143M | $127M | $214M | $285M | $202M | $264M | $239M | $123M | $189M | · | $191M | |
| Receivables | $6M | $12M | $4M | $4M | $8M | $14M | $9M | $7M | $7M | $31M | $36M | $17M | $10M | $10M | · | $11M | |
| Prepaid Expense | $6M | $6M | $6M | $11M | $18M | $25M | $18M | $11M | $11M | $10M | $10M | $9M | $10M | $18M | · | $11M | |
| Current Assets | $176M | $221M | $151M | $182M | $232M | $287M | $343M | $406M | $443M | $355M | $422M | $381M | $412M | $304M | · | $347M | |
| PP&E (Net) | $8M | $9M | $11M | $13M | $15M | $17M | $18M | $19M | $19M | $21M | $22M | $22M | $24M | $24M | · | $24M | |
| PP&E (Gross) | · | · | $38M | · | · | · | $67M | · | · | · | $64M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $27M | · | · | · | $49M | · | · | · | $42M | · | · | · | · | · | |
| Other Non-current Assets | $1M | $1M | $495.0K | $0 | $50.0K | $85.0K | $7M | $7M | $5M | $6M | $4M | $3M | $3M | $3M | · | $2M | |
| Total Assets | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Accounts Payable | $3M | $5M | $8M | $7M | $4M | $8M | $10M | $6M | $6M | $8M | $9M | $6M | $4M | $5M | · | $12M | |
| Accrued Liabilities | $6M | $5M | $15M | $13M | $12M | $12M | $13M | $13M | $10M | $7M | $15M | $11M | $10M | $6M | · | $10M | |
| Current Liabilities | $53M | $71M | $75M | $72M | $74M | $133M | $132M | $131M | $130M | $80M | $94M | $74M | $67M | $59M | · | $58M | |
| Capital Leases | $4M | $6M | $8M | $10M | $12M | $14M | $16M | $18M | $20M | $21M | $23M | $25M | $27M | $28M | · | $31M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | · | · | · | $133.0K | |
| Total Liabilities | $298M | $309M | $306M | $297M | $294M | $347M | $343M | $341M | $337M | $305M | $321M | $319M | $310M | $173M | · | $171M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7M | |
| Common Stock | $17.0K | $17.0K | $9.0K | $85.0K | $85.0K | $84.0K | $8.0K | $82.0K | $82.0K | $62.0K | $61.0K | $61.0K | $60.0K | $60.0K | · | $55.0K | |
| Retained Earnings | $-1.05B | $-1.02B | $-978M | $-931M | $-874M | $-863M | $-787M | $-714M | $-666M | $-618M | $-559M | $-590M | $-541M | $-503M | · | $-418M | |
| AOCI | $-58.0K | $-101.0K | $19.0K | $33.0K | $-13.0K | $-9.0K | $39.0K | $106.0K | $-163.0K | $-113.0K | $21.0K | $7.0K | $16.0K | $-107.0K | · | $-1M | |
| Stockholders' Equity | $-103M | $-67M | $-132M | $-87M | $-32M | $-26M | $45M | $111M | $152M | $98M | $150M | $112M | $155M | $185M | $217M | $230M | |
| Liabilities + Equity | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Shares Outstanding | 16,576,205 | 16,566,803 | 8,584,309 | 85,101,749 | 84,720,047 | 84,349,041 | 8,306,398 | 82,395,350 | 81,861,584 | 62,456,546 | 61,009,829 | 60,900,704 | 60,471,041 | 60,161,801 | · | 54,631,360 |
현금 흐름 10
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $5M | $6M | $6M | $7M | $6M | $6M | $6M | $6M | $7M | $6M | $6M | $7M | |
| Restructuring | · | $0 | $1M | $3M | $1M | $8M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-7M | · | · | · | $647.0K | · | · | · | $-14M | · | · | · | $-19M | · | · | |
| Operating Cash Flow | $-38M | $-42M | $-26M | $-38M | $-45M | $-68M | $-72M | $-65M | $9M | $-65M | $14M | $-34M | $-31M | $-61M | $-24M | $66M | |
| Investing Cash Flow | $19M | $-45M | $19M | $40M | $3M | $-16M | $87M | $147M | $-80M | $64M | $-24M | $-114M | $66M | $67M | $-38M | $-78M | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-418.0K | $103M | $-64.0K | $102.0K | $-60.0K | $66.0K | $-24.0K | $1M | $96M | $-3M | $-3M | $-6M | $138M | $9M | $12M | $30M | |
| Net Change in Cash | $-19M | $16M | $-8M | $2M | $-42M | $-84M | $16M | $84M | $26M | $-4M | $-13M | $-153M | $173M | $15M | $-50M | $18M | |
| Taxes Paid | $1.0K | $-15.0K | $64.0K | $0 | $4.0K | $7.0K | $2M | $2.0K | $15M | $10.0K | · | · | · | · | · | · |
수익성 7
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -303.8% | -204.2% | · | -499.9% | -5.2% | -393.8% | · | -797.2% | -189.4% | -435.1% | · | -260.1% | -443.5% | -333.3% | · | -84.3% | |
| Net Margin | -391.6% | -265.0% | · | -586.6% | -18.0% | -436.6% | · | -572.6% | -186.8% | -447.5% | · | -291.2% | -370.0% | -394.9% | · | -77.5% | |
| Pretax Margin | -391.6% | -265.1% | · | -586.6% | -18.1% | · | · | -572.6% | -186.8% | -447.5% | · | -280.3% | -368.6% | -391.8% | · | -77.5% | |
| EBITDA Margin | -303.8% | -195.4% | · | -499.9% | -5.2% | -382.9% | · | -797.2% | -189.4% | -421.5% | · | -260.1% | -443.5% | -320.5% | · | -84.3% | |
| ROA | -16.9% | -13.7% | · | -17.2% | -3.1% | -21.0% | · | -11.0% | -10.1% | -15.3% | · | -11.8% | -9.1% | -15.1% | · | -5.1% | |
| ROE | 56.9% | 83.0% | · | -474.8% | -19.1% | -210.4% | · | -43.6% | -31.3% | -41.1% | · | -28.8% | -21.2% | -24.7% | · | -7.6% | |
| ROIC | 28.9% | 44.3% | · | 55.5% | 10.4% | · | · | -61.1% | -32.0% | · | · | -40.7% | -30.0% | -23.0% | · | · |
유동성 및 지급능력 4
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.1 | · | 2.5 | 3.1 | 2.2 | · | 3.1 | 3.4 | 4.5 | · | 5.2 | 6.1 | 5.1 | · | 5.9 | |
| Quick Ratio | 3.2 | 3.0 | · | 2.4 | 2.9 | 2.0 | · | 3.0 | 2.9 | 3.8 | · | 4.6 | 5.5 | 4.4 | · | 5.1 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 |
효율성 2
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.2 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | |
| Receivables Turnover | 1.4 | 1.1 | · | 1.8 | 8.5 | 0.8 | · | 0.7 | 3.0 | 0.6 | · | 1.2 | 0.2 | 1.2 | · | 2.1 |
가치 평가 (TTM) 12
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $98M | $105M | · | $99M | $115M | $65M | · | $64M | $66M | $53M | · | $65M | $76M | $72M | · | $68M | |
| Net Income TTM | $-145M | $-183M | · | $-193M | $-184M | $-231M | · | $-204M | $-194M | $-196M | · | $-157M | $-134M | $-135M | · | $-116M | |
| Market Cap | $550M | $413M | · | $74M | $60M | $55M | · | $285M | $240M | $353M | · | $211M | $281M | $278M | · | $303M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $23M | |
| P/E | -4.6 | -1.9 | · | -0.4 | -0.3 | -0.2 | · | -1.3 | -1.1 | -2.0 | · | -1.3 | -1.9 | -1.8 | · | -2.3 | |
| P/S | 5.6 | 3.9 | · | 0.7 | 0.5 | 0.8 | · | 4.4 | 3.6 | 6.7 | · | 3.2 | 3.7 | 3.9 | · | 4.5 | |
| P/B | -5.3 | -6.2 | · | -0.8 | -1.9 | -2.1 | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Tangible Book | · | · | · | · | · | · | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Cash Flow | · | -9.8 | · | · | · | -0.8 | · | · | · | -5.5 | · | · | · | -4.6 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -1.1 | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.3 | |
| Earnings Yield | -22.0% | -51.5% | · | -265.5% | -314.1% | -412.3% | · | -74.6% | -89.8% | -51.1% | · | -77.0% | -51.8% | -56.5% | · | -43.8% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $102M | $62M | $154M | $68M | $62M |
| 영업이익률 % | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% |
| 순이익 | $-191M | $-227M | $-107M | $-119M | $-106M |
| 희석 EPS | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | — | — | 0.0 | 0.1 | 0.1 |
| 유동비율 | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 |
| 당좌 비율 | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 |
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 111개의 제출자 · $467.3M 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 46 (+21 이전 분기 대비) | 16 (+8 이전 분기 대비) | 20 (0 이전 분기 대비) | 19 (+5 이전 분기 대비) | +1.3M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | $43,320,887 | 1,304,846 | 9.27% | 주식 |
| BVF INC/IL | $41,559,362 | 1,251,788 | 8.89% | 주식 |
| Affinity Asset Advisors, LLC | $38,926,568 | 1,172,487 | 8.33% | 주식 |
| SAMSARA BIOCAPITAL, LLC | $35,287,350 | 1,062,872 | 7.55% | 주식 |
| Kynam Capital Management, LP | $28,968,926 | 872,558 | 6.20% | 주식 |
| ORBIMED ADVISORS LLC | $24,698,941 | 743,944 | 5.29% | 주식 |
| Balyasny Asset Management L.P. | $23,610,578 | 711,162 | 5.05% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $23,048,071 | 694,219 | 4.93% | 주식 |
| EVENTIDE ASSET MANAGEMENT, LLC | $19,430,698 | 585,262 | 4.16% | 주식 |
| Velan Capital Investment Management LP | $17,003,712 | 512,160 | 3.64% | 주식 |
| Woodline Partners LP | $15,206,563 | 458,029 | 3.25% | 주식 |
| ADAR1 Capital Management, LLC | $13,413,265 | 404,014 | 2.87% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $12,150,270 | 365,972 | 2.60% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $11,027,500 | 332,057 | 2.36% | 주식 |
| STATE STREET CORP | $10,158,503 | 305,979 | 2.17% | 주식 |
| Merck & Co., Inc. | $9,042,053 | 272,351 | 1.93% | 주식 |
| ACUTA CAPITAL PARTNERS, LLC | $8,972,333 | 270,251 | 1.92% | 주식 |
| AMERIPRISE FINANCIAL INC | $8,123,011 | 244,669 | 1.74% | 주식 |
| Point72 Asset Management, L.P. | $7,895,856 | 237,827 | 1.69% | 주식 |
| KVP Capital Advisors, LP | $7,522,290 | 226,575 | 1.61% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $6,696,042 | 201,688 | 1.43% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6,559,058 | 197,562 | 1.40% | 주식 |
| UBS Group AG | $5,407,251 | 162,869 | 1.16% | 주식 |
| Seven Fleet Capital Management LP | $3,794,182 | 159,118 | 0.81% | 주식 |
| Qube Research & Technologies Ltd | $3,539,452 | 106,610 | 0.76% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $3,460,502 | 104,232 | 0.74% | 주식 |
| CITADEL ADVISORS LLC | $3,385,205 | 101,964 | 0.72% | 주식 |
| MACKENZIE FINANCIAL CORP | $3,146,264 | 94,767 | 0.67% | 주식 |
| RENAISSANCE TECHNOLOGIES LLC | $2,865,957 | 86,324 | 0.61% | 주식 |
| MARSHALL WACE, LLP | $2,448,865 | 73,761 | 0.52% | 주식 |
| Y-Intercept (Hong Kong) Ltd | $1,855,183 | 55,879 | 0.40% | 주식 |
| Squarepoint Ops LLC | $1,843,895 | 55,539 | 0.39% | 주식 |
| XTX Topco Ltd | $1,732,011 | 52,169 | 0.37% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1,636,826 | 49,302 | 0.35% | 주식 |
| Sigma Planning Corp | $1,494,664 | 45,020 | 0.32% | 주식 |
| Fisher Asset Management, LLC | $1,171,794 | 35,295 | 0.25% | 주식 |
| Elmind Capital, LP | $1,063,628 | 32,037 | 0.23% | 주식 |
| D. E. Shaw & Co., Inc. | $1,000,250 | 30,128 | 0.21% | 주식 |
| GOLDMAN SACHS GROUP INC | $975,814 | 29,392 | 0.21% | 주식 |
| Trexquant Investment LP | $917,515 | 27,636 | 0.20% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $909,116 | 27,383 | 0.19% | 주식 |
| BANK OF AMERICA CORP /DE/ | $863,897 | 26,021 | 0.18% | 주식 |
| RHUMBLINE ADVISERS | $684,845 | 20,628 | 0.15% | 주식 |
| JPMORGAN CHASE & CO | $625,079 | 18,743 | 0.13% | 주식 |
| BlackRock, Inc. | $595,276 | 17,930 | 0.13% | 주식 |
| SEI INVESTMENTS CO | $544,048 | 16,387 | 0.12% | 주식 |
| Informed Momentum Co LLC | $538,902 | 16,232 | 0.12% | 주식 |
| DEUTSCHE BANK AG\ | $516,692 | 15,563 | 0.11% | 주식 |
| RBF Capital, LLC | $507,030 | 15,272 | 0.11% | 주식 |
| WELLS FARGO & COMPANY/MN | $449,661 | 13,544 | 0.10% | 주식 |
| AJU IB Investment Co., Ltd. | $435,925 | 17,500 | 0.09% | 주식 |
| Bank of New York Mellon Corp | $434,522 | 13,088 | 0.09% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $368,520 | 11,100 | 0.08% | 콜 옵션 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $365,200 | 11,000 | 0.08% | 풋 옵션 |
| MetLife Investment Management, LLC | $312,113 | 9,401 | 0.07% | 주식 |
| Walleye Capital LLC | $308,959 | 9,306 | 0.07% | 주식 |
| Integrated Quantitative Investments LLC | $296,775 | 8,939 | 0.06% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $279,743 | 8,426 | 0.06% | 주식 |
| Lighthouse Investment Partners, LLC | $277,818 | 8,368 | 0.06% | 주식 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $242,792 | 7,313 | 0.05% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $242,360 | 7,300 | 0.05% | 주식 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $232,433 | 7,001 | 0.05% | 주식 |
| Persistent Asset Partners Ltd | $218,091 | 6,569 | 0.05% | 주식 |
| CITIGROUP INC | $216,995 | 6,536 | 0.05% | 주식 |
| Verdad Advisers, LP | $212,480 | 6,400 | 0.05% | 주식 |
| Invesco Ltd. | $211,119 | 6,359 | 0.05% | 주식 |
| HSBC HOLDINGS PLC | $205,722 | 6,234 | 0.04% | 주식 |
| TWO SIGMA ADVISERS, LP | $203,401 | 17,580 | 0.04% | 주식 |
| NEW YORK STATE COMMON RETIREMENT FUND | $185,920 | 5,600 | 0.04% | 주식 |
| MORGAN STANLEY | $181,870 | 5,478 | 0.04% | 주식 |
| Vanguard Global Advisers, LLC | $180,774 | 5,445 | 0.04% | 주식 |
| Police & Firemen's Retirement System of New Jersey | $156,173 | 4,704 | 0.03% | 주식 |
| Nuveen, LLC | $131,837 | 3,971 | 0.03% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $119,520 | 3,600 | 0.03% | 주식 |
| Nuveen Asset Management, LLC | $103,678 | 56,347 | 0.02% | 주식 |
| BARCLAYS PLC | $84,228 | 2,537 | 0.02% | 주식 |
| NORTHERN TRUST CORP | $83,100 | 2,503 | 0.02% | 주식 |
| State of Wyoming | $53,718 | 1,618 | 0.01% | 주식 |
| Legal & General Group Plc | $51,394 | 1,548 | 0.01% | 주식 |
| Ameritas Investment Partners, Inc. | $48,074 | 1,448 | 0.01% | 주식 |
| FMR LLC | $44,388 | 1,337 | 0.01% | 주식 |
| Russell Investments Group, Ltd. | $42,330 | 1,275 | 0.01% | 주식 |
| VANGUARD GROUP INC | $36,307 | 3,138 | 0.01% | 주식 |
| Tower Research Capital LLC (TRC) | $28,751 | 866 | 0.01% | 주식 |
| Point72 Asia (Singapore) Pte. Ltd. | $26,943 | 31,026 | 0.01% | 주식 |
| CWM, LLC | $24,487 | 983 | 0.01% | 주식 |
| ROYAL BANK OF CANADA | $23,000 | 687 | 0.00% | 주식 |
| Owl Creek Wealth Partners LLC | $16,302 | 491 | 0.00% | 주식 |
| ACADIAN ASSET MANAGEMENT LLC | $12,405 | 373,839 | 0.00% | 주식 |
| Sterling Capital Management LLC | $9,329 | 281 | 0.00% | 주식 |
| Quantbot Technologies LP | $6,673 | 201 | 0.00% | 주식 |
| Physician Wealth Advisors, Inc. | $6,043 | 182 | 0.00% | 주식 |
| MERCER GLOBAL ADVISORS INC /ADV | $3,718 | 112 | 0.00% | 주식 |
| OSAIC HOLDINGS, INC. | $3,320 | 100 | 0.00% | 주식 |
| PNC Financial Services Group, Inc. | $2,058 | 62 | 0.00% | 주식 |
| Fortitude Family Office, LLC | $1,859 | 56 | 0.00% | 주식 |
| Bogart Wealth, LLC | $1,660 | 50 | 0.00% | 주식 |
| Parallel Advisors, LLC | $1,560 | 47 | 0.00% | 주식 |
| NISA INVESTMENT ADVISORS, LLC | $1,461 | 44 | 0.00% | 주식 |
| Accredited Wealth Management, LLC | $869 | 5 | 0.00% | 주식 |
회사 내부자 27 명의 내부자 · 14 임원 · 14 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| William J Newell | CEO | 2023년 3월 3일 M | 164,816 | 0 | 0 | $0 |
| Gregory K. Chow | CFO | 2026년 6월 2일 M | 4,725 | 0 | 0 | $0 |
| Edward C Albini | CFO and Secretary | 2023년 3월 3일 M | 87,693 | 0 | 0 | $0 |
| Jane Chung | President and COO | 2023년 12월 1일 A | 31,698 | 0 | 0 | $0 |
| Hans-Peter Gerber | Chief Scientific Officer | 2023년 9월 18일 A | — | 0 | 0 | $0 |
| Brunilda Shtylla | Chief Business Officer | 2023년 8월 28일 S | 0 | 0 | 0 | $0 |
| Nicki Vasquez | Chief Port. Strat & Alnce Ofcr | 2023년 7월 12일 M | 24,988 | 0 | 0 | $0 |
| Venkatesh Srinivasan | Chief Tech Op Officer | 2023년 5월 1일 A | — | 0 | 0 | $0 |
| Trevor Hallam | Pres. Rsrch & Cf. Sctific Ofcr | 2023년 4월 14일 M | 100,368 | 0 | 0 | $0 |
| Anne Elizabeth Borgman | Chief Medical Officer | 2023년 3월 15일 A | — | 0 | 0 | $0 |
| Anik Shabbir | Chief Technical Ops. Officer | 2023년 3월 3일 M | 40,827 | 0 | 0 | $0 |
| Linda A Fitzpatrick | Chief People & Comm. Officer | 2023년 3월 3일 M | 52,690 | 0 | 0 | $0 |
| Arturo Molina MD | Chief Medical Officer | 2022년 3월 5일 M | 37,736 | 0 | 0 | $0 |
| Stephen Worsley | Chief Business Officer | 2019년 1월 29일 A | — | 0 | 0 | $0 |
| Heidi Hunter | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Michael Dybbs | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Jon Marc Wigginton | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Sukhi Jagpal | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Joseph M Lobacki | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Daniel H Petree | 이사 | 2026년 6월 5일 A | 18,601 | 0 | 0 | $0 |
| Connie Matsui | 이사 | 2026년 6월 5일 A | 50,000 | 1 | 0 | $40,000 |
| James P Panek | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| John Gordon Freund | 이사 | 2023년 6월 8일 A | 56,327 | 0 | 0 | $0 |
| Shalini Sharp | 이사 | 2022년 6월 6일 A | — | 0 | 0 | $0 |
| Daniel Janney | 이사 | 2019년 6월 17일 A | 1,944,901 | 0 | 0 | $0 |
| Michael Jay Ross | 이사 | 2018년 10월 1일 C | 18,248 | 0 | 0 | $0 |
| Bryan V Lawlis | 이사 | 2018년 9월 26일 A | — | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 1 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| SVLSF V, LLC, SV Life Sciences Fund V, L.P., SV Life Sciences Fund V Strategic Partners, L.P., SV Life Sciences Fund V (GP), L.P., ILSF III, LLC, International Life Sciences Fund III (GP), L.P., International Life Sciences Fund III Co-Investment, L.P., International Life Sciences Fund III (LP1), L.P., International Life Sciences Fund III Strategic Partners, L.P. | 2018년 10월 9일 | — | 최초 제출 | 수동적 투자 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 15 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.43% | 3,826 SH | 2026년 8월 8일 | 일간 |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.25% | 28,745 SH | 2026년 8월 8일 | 일간 |
| IWC · iShares Trust | 0.09% | 54,216 SH | 2026년 8월 8일 | 일간 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.03% | 11,715 SH | 2026년 8월 8일 | 일간 |
| IWN · iShares Trust | 0.02% | 121,308 SH | 2026년 8월 8일 | 일간 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 91,894 SH | 2026년 8월 8일 | 일간 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.01% | 16,520 SH | 2026년 8월 8일 | 일간 |
| IWM · iShares Trust | 0.01% | 398,610 SH | 2026년 8월 8일 | 일간 |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 177,152 SH | 2026년 8월 8일 | 일간 |
| VHT · VANGUARD WORLD FUND | 0.01% | 47,358 SH | 2026년 8월 8일 | 일간 |
| IWO · iShares Trust | 0.00% | 22,665 SH | 2026년 8월 8일 | 일간 |
| ITOT · iShares Trust | 0.00% | 29,451 SH | 2026년 8월 8일 | 일간 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 501,524 SH | 2026년 8월 8일 | 일간 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2,670 SH | 2026년 8월 8일 | 일간 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 1,330 SH | 2026년 8월 8일 | 일간 |